梯瓦制药Teva Pharmaceutical Industries Limited (TEVA) 2003年年度报告「NYSE」.pdf

1、UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 20-F?REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934 Or ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,200

2、3 Or?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number:0-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of Registrant as specified in its charter)N/A ISRAEL(Translation of Registrants name into E

3、nglish)(Jurisdiction of incorporation or organization)5 Basel Street P.O.Box 3190 Petach Tikva 49131,Israel (Address of principal executive offices)Securities registered or to be registered pursuant to Section 12(b)of the Act:Title of each class Name of each exchange on which registered NoneNoneSecu

4、rities registered or to be registered pursuant to Section 12(g)of the Act:American Depositary Shares(as evidenced by American Depositary Receipts),each representing one Ordinary Share (Title of Class)Securities for which there is a reporting obligation pursuant to Section 15(d)of the Act:None Indica

5、te the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report.277,668,835 Ordinary Shares 198,371,227 American Depositary Shares Indicate by check mark whether the registrant(1)has filed all reports required t

6、o be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No?Indicate by check mark which financi